Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.

Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song IH.

Ann Rheum Dis. 2019 Jul 30. pii: annrheumdis-2019-215764. doi: 10.1136/annrheumdis-2019-215764. [Epub ahead of print]

2.

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.

Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC.

Arthritis Rheumatol. 2019 Jul 9. doi: 10.1002/art.41032. [Epub ahead of print]

PMID:
31287230
3.

Correction to: PANLAR consensus statement on biosimilars.

Kowalski SC, Benavides JA, Beltrán PA, Galarza-Maldonado C, Caballero-Uribe CV, Soriano ER, Pineda C, Azevedo VF, Avila-Pedretti G, Babini AM, Cachafeiro-Vilar A, Cifuentes-Alvarado M, Cohen SB, Díaz PE, Diaz-Coto JF, Encalada C, Garro B, Sariego IAG, Guibert-Toledano M, Rodriguez VJK, Lopez MEL, Ortega AP, Russell AS, Santos-Moreno P, Terán IS, Vargas A, Vásquez G, Xavier RM, Firedman DXX, Mysler E, Kay J.

Clin Rheumatol. 2019 Jul;38(7):2021-2022. doi: 10.1007/s10067-019-04592-4.

PMID:
31111361
4.

PANLAR consensus statement on biosimilars.

Kowalski SC, Benavides JA, Roa PAB, Galarza-Maldonado C, Caballero-Uribe CV, Soriano ER, Pineda C, Azevedo VF, Avila-Pedretti G, Babini AM, Cachafeiro-Vilar A, Cifuentes-Alvarado M, Cohen SB, Díaz PE, Soto LD, Encalada C, Garro B, Sariego IAG, Guibert-Toledano M, Rodriguez VJK, Lopez MEL, Ortega AP, Russell AS, Santos-Moreno P, Terán IS, Vargas A, Vásquez G, Xavier RM, Firedman DXX, Mysler E, Kay J.

Clin Rheumatol. 2019 May;38(5):1485-1496. doi: 10.1007/s10067-019-04496-3. Epub 2019 Mar 27. Erratum in: Clin Rheumatol. 2019 May 20;:. Roa PA [corrected to Beltrán PA], Soto LD [corrected to Diaz-Coto JF].

PMID:
30915652
5.

Similar and mimics: Latin America biosimilar regulations.

Lizarraga A, Mysler E.

Int J Rheum Dis. 2019 Jan;22(1):6-8. doi: 10.1111/1756-185X.13461. Review. No abstract available.

PMID:
30689310
6.

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.

Chadwick L, Zhao S, Mysler E, Moots RJ.

Curr Rheumatol Rep. 2018 Nov 9;20(12):84. doi: 10.1007/s11926-018-0799-0. Review.

7.

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.

Zhao S, Chadwick L, Mysler E, Moots RJ.

Curr Rheumatol Rep. 2018 Aug 9;20(10):57. doi: 10.1007/s11926-018-0769-6. Review.

8.

Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.

Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E.

BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4. Review.

PMID:
29790131
9.

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.

Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R.

J Rheumatol. 2018 Aug;45(8):1085-1092. doi: 10.3899/jrheum.170344. Epub 2018 Apr 15.

10.

Work disability in Argentinian patients with systemic lupus erythematosus is prevalent and it is due to ethnic, socioeconomic and disease-related factors.

Pisoni CN, Muñoz SA, Tamborenea MN, García M, Curti A, Cappuccio A, Rillo O, Imamura PM, Schneeberger E, Ballent M, Cousseau ML, Velasco Zamora J, Saurit V, Toloza S, Danielsen MC, Bellomio VI, Graf C, Paira S, Cavallasca J, Pons Estel B, Moreno JLC, Díaz M, Alba P, Verando M, Tate G, Mysler E, Sarano J, Civit EE, Risueño F, Álvarez Sepúlveda P, Larroude MS, Méndez MF, Conforti A, Sohn D.

Int J Rheum Dis. 2018 Nov;21(11):2019-2027. doi: 10.1111/1756-185X.13269. Epub 2018 Apr 2.

PMID:
29611343
11.

Etanercept for the treatment of rheumatoid arthritis.

Zhao S, Mysler E, Moots RJ.

Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27. Review.

PMID:
29482402
12.

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

D'Agostino MA, Alten R, Mysler E, Le Bars M, Ye J, Murthy B, Heitzmann J, Vadanici R, Ferraccioli G.

Clin Rheumatol. 2017 Dec;36(12):2655-2665. doi: 10.1007/s10067-017-3788-1. Epub 2017 Aug 18.

13.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators.

Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16.

PMID:
28629665
14.

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

Moots R, Azevedo V, Coindreau JL, Dörner T, Mahgoub E, Mysler E, Scheinberg M, Marshall L.

Curr Rheumatol Rep. 2017 Jun;19(6):37. doi: 10.1007/s11926-017-0658-4. Review.

15.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

16.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

17.

Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.

Castañeda OM, Romero FJ, Salinas A, Citera G, Mysler E, Rillo O, Radominski SC, Cardiel MH, Jaller JJ, Alvarez-Moreno C, Ponce de Leon D, Castelli G, García EG, Kwok K, Rojo R.

J Clin Rheumatol. 2017 Jun;23(4):193-199. doi: 10.1097/RHU.0000000000000498.

PMID:
28145906
18.

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.

Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, Jacobs I.

Rheumatol Int. 2016 May;36(5):613-25. doi: 10.1007/s00296-016-3444-0. Epub 2016 Feb 27. Review.

19.
20.

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).

Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Bao M, Rowell L, Davies C, Mysler EF.

Ann Rheum Dis. 2016 Jan;75(1):68-74. doi: 10.1136/annrheumdis-2015-207281. Epub 2015 Jun 8.

21.

Biosimilars: clinical interpretation and implications for drug development.

Mysler E.

Curr Rheumatol Rep. 2015 Feb;17(2):8. doi: 10.1007/s11926-014-0483-y. Review.

PMID:
25618574
22.

The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.

Keiserman M, Codreanu C, Handa R, Xibillé-Friedmann D, Mysler E, Briceño F, Akar S.

Expert Rev Clin Immunol. 2014 Aug;10(8):1049-57. doi: 10.1586/1744666X.2014.926219. Epub 2014 Jun 25. Review.

PMID:
24961616
23.

Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies.

Castañeda-Hernández G, Szekanecz Z, Mysler E, Azevedo VF, Guzman R, Gutierrez M, Rodríguez W, Karateev D.

Joint Bone Spine. 2014 Dec;81(6):471-7. doi: 10.1016/j.jbspin.2014.03.019. Epub 2014 Jun 20. Review.

PMID:
24956990
24.

Work instability in rheumatoid arthritis patients from Argentina: prevalence and associated factors.

Tamborenea MN, Pisoni C, Toloza S, Mysler E, Tate G, Pereira D, García Carrasco M, Quintero J, Cappuccio A, Granel A, Lazaro M, Arturi P, Citera G, Velazco Zamora J, Saurit V, Alvarellos A, Pons Estel SB, Danielsen C, Graf C, Paira S, Ceccatto F, Cavallasca J, Civit E, Moreno J, Estevez A, Diaz M, Verando M, Catalan Pellet A, Gomez G, Maid P, Beron A, Salvatierra G, Mendez M, Cusa A, Rillo O, Paez M, Larraude M, Sohn D, Gallo M, Conforti A, Malah V, Tate P, Baños A.

Rheumatol Int. 2015 Jan;35(1):107-14. doi: 10.1007/s00296-014-3062-7. Epub 2014 Jun 20.

PMID:
24948375
25.

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R.

J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1.

26.

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).

Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, Rowell L, Bao M, Mysler EF.

Ann Rheum Dis. 2014 Jan;73(1):69-74. doi: 10.1136/annrheumdis-2013-203523. Epub 2013 Jul 31.

27.

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P.

Arthritis Rheum. 2013 Sep;65(9):2368-79. doi: 10.1002/art.38037.

28.

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W.

Arthritis Rheum. 2013 Apr;65(4):1011-21. doi: 10.1002/art.37824.

29.

Work productivity in rheumatoid arthritis: relationship with clinical and radiological features.

Chaparro Del Moral R, Rillo OL, Casalla L, Morón CB, Citera G, Cocco JA, Correa Mde L, Buschiazzo E, Tamborenea N, Mysler E, Tate G, Baños A, Herscovich N.

Arthritis. 2012;2012:137635. doi: 10.1155/2012/137635. Epub 2012 Dec 19.

30.

Biosimilars in rheumatology: a view from Latin America.

Mysler E, Scheinberg M.

Clin Rheumatol. 2012 Sep;31(9):1279-80. doi: 10.1007/s10067-012-2068-3. Epub 2012 Aug 24. No abstract available.

PMID:
22918492
31.

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R.

Arthritis Rheum. 2011 Oct;63(10):2854-64. doi: 10.1002/art.30463.

32.

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.

Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A.

Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063. Epub 2011 May 3.

33.

Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.

Tamborenea MN, Tate G, Mysler E, Debonis J, Schijedman A.

Rheumatol Int. 2010 Mar;30(5):613-6. doi: 10.1007/s00296-009-1027-z. Epub 2009 Jul 4.

PMID:
19578852
34.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group.

J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15.

35.
36.

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.

Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, Litschig S, Krammer G, Tate GA.

Rheumatology (Oxford). 2007 Jul;46(7):1126-32. Epub 2007 May 3.

PMID:
17478464
37.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH; TARGET Study Group.

Lancet. 2004 Aug 21-27;364(9435):675-84.

PMID:
15325832
38.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group.

Lancet. 2004 Aug 21-27;364(9435):665-74.

PMID:
15325831
39.

Lumiracoxib (Prexige): a new selective COX-2 inhibitor.

Mysler E.

Int J Clin Pract. 2004 Jun;58(6):606-11. Review.

PMID:
15311562
40.

Catastrophic antiphospholipid syndrome complicating orthotopic liver transplantation.

Villamil A, Sorkin E, Basta MC, Mysler E, Macias S, Pekolj J, Ciardullo M, Eleta F, de Santibañes E, Allievi A, Gadano A.

Lupus. 2003;12(2):140-3.

PMID:
12630760
41.

A reversible bilateral renal artery stenosis in association with antiphospholipid syndrome.

Remondino GI, Mysler E, Pissano MN, Furattini MC, Basta MC, Presas JL, Allievi A.

Lupus. 2000;9(1):65-7.

PMID:
10713649
42.

Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.

Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB.

Arthritis Rheum. 1995 Dec;38(12):1735-7.

PMID:
8849344
43.

Ciprofloxacin reactions mimicking lupus flares.

Mysler E, Paget SA, Kimberly R.

Arthritis Rheum. 1994 Jul;37(7):1112-3. No abstract available.

PMID:
8024622
44.

The apoptosis-1/Fas protein in human systemic lupus erythematosus.

Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon KB.

J Clin Invest. 1994 Mar;93(3):1029-34.

Supplemental Content

Loading ...
Support Center